“You can just stop taking it once you hit your goal weight.”
What the evidence shows
In randomized human trials, stopping a GLP-1 medication typically leads to substantial weight regain. In the STEP 1 extension, people regained about two-thirds of their lost weight within a year of stopping semaglutide and lifestyle support; in STEP 4, those switched off the drug regained roughly 7% of body weight over the next year while those who continued kept losing. Obesity behaves as a chronic condition: the underlying appetite physiology largely returns once the drug is gone.
What we still don’t know
We don't have strong evidence on who, if anyone, can stop and reliably keep the weight off, or for how long. The evidence base for tapering to a lower "maintenance" dose rather than fully stopping is still limited (supported-but-limited), and the long-term role of intensive lifestyle change after stopping is not fully mapped.
Why the claim misleads
The claim frames a goal-weight number as a finish line, when the trials show reaching the number does not permanently reset the biology that drove the weight. Treating "stop at goal" as a default plan, rather than a clinician-guided decision among continue / taper / stop / restart, sets most people up for predictable regain.
Graded by The Peptide Era · evidence, not hype